Daily Stock List
Vantage mHealthcare, Inc. (VNTH)
TheMicrocapNews and BUYINS.NET reported earlier on Vantage mHealthcare, Inc. (VNTH), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Vantage mHealthcare, Inc. is a mobile health technology company listed on the OTC Markets Group’s OTCQB. It is developing personalized and point-of-care screening using applications (apps) based on chemical sensing residing within a Bluetooth device that works with any smartphone, tablet, or laptop. Vantage Health is the first non-invasive, inexpensive, mobile, early cancer screening and monitoring platform. The Company has offices in Mountain View, California and New York, New York.
This past January, Vantage mHealthcare announced that its corporate name was officially changed to Vantage mHealthcare, Inc. (from Vantage Health, Inc.) to better align the strategic direction of the Company within the growing and innovative mobile healthcare technology sector.
Further to the name change, it amended its Certificate of Incorporation. It is now a Delaware corporation and it increased its authorized shares outstanding from 250,000,000 to 500,000,000 shares and reclassified such capital stock into 450,000,000 shares of common stock, par value $0.001, and 50,000,000 shares of preferred stock, par value $0.001. Vantage mHealthcare said it has no immediate plans to use the additional shares.
Vantage mHealthcare’s first product is the Vantage Health Sensor, which is in development. It is the union of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The expectation is that the first mobile app will be for lung cancer screening with additional mobile healthcare apps in the planning stages.
The Company’s mission is to commercialize mobile breath sensor technologies, which permit Health Care providers (HCPs) to better manage the health care range - from managing illness to wellness.
Today, Vantage mHealthcare announced that its manufacturer expects to deliver 100 Health Sensors over the next month to hospitals and research facilities in the U.S. and New Zealand, advancing to the next phase of its research and development (R&D) process, to prepare for human clinical trials. Over the past six months, Vantage has invested considerable time, effort, and resources in improving the ergonomic design of the hand-held device. It has added blue-tooth communication capabilities to the unit, increased the sensitivity of the nanotube-based chemical sensors, refined the software algorithms used to interpret the raw sensor data, and automated the production of the critical components.
Vantage mHealthcare, Inc. (VNTH), closed Monday's trading session at $0.0529, up 17.56%, on 635,609 volume with 64 trades. The average volume for the last 60 days is 282,566 and the stock's 52-week low/high is $0.0201/$0.35.
Arrayit Corp. (ARYC)
Pumps and Dumps, Goldman Small Cap Research, PennyStocks24, and Information Solutions Group reported earlier on Arrayit Corp. (ARYC), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Founded in 1993, Arrayit Corp. is a top life sciences company headquartered in Sunnyvale, California. It provides innovative products and services to empower scientists and clinicians to explore the human genome and the genomes of plants and animals. Arrayit leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment, and cure.
The Company’s worldwide business position leverages its broadly used patented microarray manufacturing platform and VIP™ genotyping technology. It has leveraged its proprietary life sciences platform to develop OvaDx®. This is the first definitive diagnostic screening test for early stage detection of ovarian cancer. Additionally, Arrayit has pipeline diagnostic tests for Parkinson’s Disease, Plavix®, Male Fertility, and Prostate Cancer.
Its products include Microarrayers, Microarray Scanners, DNA Microarrays, Protein Microarrays, Microarray Printing, Microarray Substrate Slides, Microarray Instruments, Amplification & Labeling, Microarray Tools, Buffers & Solutions, Microarray Cleanrooms, Books & Software, CGH Microarrays, as well as Microarray Platforms.
Arrayit announced this past December that it signed a Cooperative Research and Development Agreement (CRADA) with the United States Department of Agriculture (USDA) entitled "Rapid and Cost Effective Detection Technologies for Noroviruses and other Foodborne Pathogens." With this agreement, Arrayit and the USDA Agricultural Research Service (USDA ARS) will develop and validate a rapid, portable, cost-effective and high-throughput detection system for the surveillance of multiple bacterial and viral foodborne pathogens.
The expected outcome is a commercial test, which will be extensively deployed throughout the lifecycle of food production and distribution to ensure that the food supply is safe for consumption. Arrayit and the USDA will use Arrayit's patented and proprietary DNA microarray platform and the USDA's patent pending method to detect DNA sequences present in potentially life-threatening foodborne pathogens that periodically contaminate fruits, vegetables, meats, poultry, and dairy products.
Recently, Arrayit announced that it is debuting major new products and services for the billion dollar genomics and proteomics markets in its new full color, image-rich 2015/2016 catalog. Arrayit High-Seq™ genomic labeling kits, HuProt™ v2.0 19K human proteome microarrays, InnoScan® 910 and 1100 microarray scanners, series 3 glass consumables, and TissueMax™ personal tissue microarrayers featured in the new catalog are hurrying basic research and clinical medicine to improve healthcare, agriculture, as well as food safety.
Arrayit Corp. (ARYC), closed Monday's trading session at $0.085, up 0.12%, on 12,206 volume with 2 trades. The average volume for the last 60 days is 51,613 and the stock's 52-week low/high is $0.0513/$0.28.
World Moto, Inc. (FARE)
Pumps and Dumps, PennyStocks24, and Stock Twiter reported earlier on World Moto, Inc. (FARE), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
OTC Bulletin Board-listed World Moto, Inc. manufactures and supplies taxi meters for the motorcycle taxi industry. It provides portable taxi meters and black boxes for motorcycles. World Moto invented the Moto-Meter™, a device that CNN, Newsweek, Wired, and Moneylife, among others, are calling "the world's first motorcycle taxi meter" and "world's first portable taxi meter" and "first-ever black box for motorcycles." Furthermore, World Moto is the creator of Wheelies™ and Yes™.
The Moto-Meter™ is the first taxi meter designed specifically for the large motorcycle taxi market. Important features of the product include a device that is portable, tamperproof, ruggedized, and insect resistant. The Moto-Meter™ incorporates GPS and MEMS technology to calculate fares.
The Moto-Meter™ serves as a black box that records important data. This includes speed, acceleration, and braking information. The LED screen displays "infotainment" and geographically relevant ads. This includes nearby shops and restaurants, for the length of the ride. The advertisements can bring in revenue for the driver and World Moto.
World Moto’s Yes™ (an e-service) is a personal retail and delivery service. It makes local commerce as convenient as the Internet. A user simply taps an application (app) and gets refreshments, toothpaste, and more, or any necessity delivered anywhere in under 15 minutes. In addition, the Company’s Wheelies™ displays static and streaming media on the wheels of motorcycles and automobiles. This provides an innovative and new mobile medium for advertising, broadcasting, self-expression, and also publishing.
World Moto recently announced that the Company was awarded a patent on its Moto-Meter™ technology in the Dominican Republic until 2031. It has filed for patent prosecution of its Moto-Meter™ technology in 61 countries throughout Asia, Africa, Europe and the Americas. World Moto stated that these countries were carefully chosen to cover most of the world's mototaxi and autorickshaw fleets and population.
The Dominican Republic granted the patent as filed. There were no changes or office actions required on any of World Moto’s 28 claims. It will remain in force until February 8th, 2031. World Moto announced in April 2014 that it was awarded a patent on the Moto-Meter™ technology until 2033 in Morocco.
Last week, World Moto announced that it launched the Yes™ application for Android devices on Google Play in advance of commercial operation of its Yes™ platform. The Company is preparing for the commencement of commercial operation of Yes™, today, having completed a successful soft launch of the platform.
World Moto, Inc. (FARE), closed Monday's trading session at $0.0314, up 15.23%, on 1,154,662 volume with 54 trades. The average volume for the last 60 days is 1,345,577 and the stock's 52-week low/high is $0.011/$0.105.
Relmada Therapeutics, Inc. (RLMD)
StreetAuthority Financial, Investors Alley, Dividend Opportunities, Wallstreetbuzz, Investopedia, ProfitableTrading, and WallstreetsHotteststocks reported on Relmada Therapeutics, Inc. (RLMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Relmada Therapeutics, Inc. is a clinical-stage, specialty pharmaceutical company based in New York City. It concentrates on developing novel versions of proven drug products in combination with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. Relmada Therapeutics’ shares trade on the OTC Markets Group’s OTCQB.
The Company has a diverse portfolio of four lead products at different stages of development. These products include LevoCap ER, d-Methadone, MepiGel, and BuTab ER. LevoCap ER is a proprietary once-a-day extended release dosage form of the opioid analgesic levorphanol. LevoCap ER is in an abuse deterrent drug delivery system. It is a new tamper-resistant, extended release form of levorphanol.
Relmada Therapeutics’ d-Methadone is the d optical isomer of racemic methadone and an antagonist at the N-methyl-D-aspartate (NMDA) receptor. In addition, the Company’s MepiGel is a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.
Its BuTab ER is a proprietary once-a-day extended release dosage form of oral buprenorphine. It is undergoing development for the treatment of chronic moderate to moderately severe pain and opioid dependence.
Relmada Therapeutics entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER. Gavril Pasternak, MD, PhD, of MSKCC is the lead investigator for these studies.
Relmada Therapeutics announced this past December that it received a No Objection Letter (NOL) from Health Canada to conduct the first pharmacokinetic and pharmacodynamic study with d-Methadone, the Company’s N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain, in Canada. Neuropathic pain is defined as a disorder of the sensorimotor system. It is clearly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. Relmada Therapeutics also announced in December that the first cohort of subjects was dosed in a pharmacokinetic and pharmacodynamic study with d-Methadone.
Last month, Relmada Therapeutics announced that it chose the formulations to be advanced into clinical studies for MepiGel. The Company is planning single and multiple dose Phase I studies in healthy subjects with the selected MepiGel formulations later in 2015. The data from the studies will inform the design of a subsequent Phase 2 proof of concept study in patients suffering from neuropathic pain.
Moreover, in February, Relmada Therapeutics announced that it filed a Clinical Trial Application (CTA) with Heath Canada to conduct a pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (BuTab). It is planning a Phase 1 study designed to assess the safety, tolerability, as well as pharmacokinetics of BuTab in healthy subjects. The safety and pharmacokinetic data from this study will inform the design of subsequent clinical pharmacology studies for opioid dependence and potential regulatory filing for this indication. It will also inform the design of a Phase 3 study in chronic pain under the abbreviated 505(b)(2) regulatory pathway.
Relmada Therapeutics, Inc. (RLMD), closed Monday's trading session at $2.78, up 4.93%, on 231,229 volume with 220 trades. The average volume for the last 60 days is 30,050 and the stock's 52-week low/high is $1.50/$4.00.
Millennium HealthCare, Inc. (MHCC)
PennyStocks24, Stock Onion, Planet Penny Stocks, Buzz Stocks, PennyStockProphet, SecretStockPromo, Penny Pick Finders, TheMicrocapNews, and SmallCapVoice reported on Millennium HealthCare, Inc. (MHCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Millennium HealthCare, Inc., via its wholly-owned operating subsidiaries, provides primary care physician practices, physician groups, and healthcare facilities of all sizes with front-line medical devices centered primarily on preventive care through early detection. The OTCQB-listed Company operates in three segments: Coding, Device, and Vascular. Millennium Medical Devices (MMD) is a wholly-owned subsidiary of Millennium Healthcare. Millennium HealthCare has its headquarters in Garden City, New York.
The Company purchases, supplies, and distributes innovative medical devices and equipment with an emphasis on prevention and early detection. In addition, it provides physician practice development, support, and administration services for physician facilities and practices chiefly for vascular disorders. This includes peripheral arterial disease of the lower extremities. Additionally, Millennium HealthCare offers support and services specializing in medical procedure billing and collections, medical procedure coding, call and message management, and emergency dispatch.
The design of Millennium HealthCare VasoScan™ is to analyze Autonomic Nervous System (ANS) function, Stress, and Peripheral Blood Circulation. It provides objective data to assist in assessing disorders. These include depression, anxiety, sleep disorder, poor concentration, mental/physical stress degree, chronic fatigue, as well as blood circulation.
Millenium’s subsidiary, MMD, signed an exclusive agreement with CDx Diagnostics for distribution of DermCDx™, a brush biopsy test kit used to confirm suspected basal cell carcinoma (BCC). DermCDx is a minimally invasive test. It combines a patented brush biopsy sampling instrument with computer-assisted three dimensional laboratory analysis.
Millennium HealthCare, through MMD, has an exclusive agreement with CDx Diagnostics to distribute its OralCDx brush biopsy test kit. OralCDx is a non-invasive test used to test dysplasia (the small white and red tissue spots commonly found in the mouth) to rule out precancerous change. The test has previously been available to dentists across the country. By way of this exclusive collaboration, Primary Care Physicians will be able to administer this test to their patients.
Millennium HealthCare, Inc. (MHCC), closed Monday's trading session at $0.07, up 74.56%, on 646,271 volume with 54 trades. The average volume for the last 60 days is 490,658 and the stock's 52-week low/high is $0.032/$1.50.
Cemtrex, Inc. (CTEI)
Greenbackers, PennyStocks24, FeedBlitz, and Market Pulse reported earlier on Cemtrex, Inc. (CTEI), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2000, Cemtrex, Inc. is a diversified global company providing a range of products, systems, and solutions in a wide spectrum of industries to meet contemporary technological challenges. The Company, by way of its wholly-owned subsidiaries, provides electronic manufacturing services of custom engineered printed circuit board assemblies, emission monitors & instruments for industrial processes, and environmental control & air filtration systems for industries and utilities. Cemtrex is headquartered in Farmingdale, New York. The Company’s shares trade on the OTC Bulletin Board.
Its Environmental & Process Technologies business provides Air Pollution Control Systems, Industrial Dust Filtration, Continuous Emissions Monitoring Systems, and Process Analysis Systems. Cemtrex’s Electronics Manufacturing and Cabling Solutions business provides Electronic Design & Prototypes, New Product Development, Contract Manufacturing, Complete Box Builds, as well as Agile Manufacturing.
Cemtrex has refocused on strengthening its core environmental business. In addition, in October of 2013, the Company completed the acquisition of ROB Group, an electronics manufacturer.
In February, Cemtrex announced its Q1 consolidated results of operations for the three months ended December 31, 2014. Net sales for three months ended December 31, 2014 increased by 54 percent, to $13,842,789 from $8,964,380 for the three months ended December 31, 2013. Cemtrex had net profit of $396,872, for the three month period ended December 31, 2014 versus a net income of $416,552 for the three month period ended December 31, 2013. This represents a decrease of 5 percent.
Last week, Cemtrex announced that its Romanian manufacturing center recently completed its ISO 9001:2008 certification. ISO 9001:2008 sets out the criteria for a quality management system and is the only standard in the family that can be certified to, and the ISO 9000 family addresses different aspects of quality management and contains some of ISO's best known standards.
Furthermore, last week, Cemtrex announced that it developed a new In-situ NDIR Analyzer for continuous emissions monitoring applications: the IS 2500 Multi Gas Analyzer. The IS 2500 Multi Gas Analyzer combines the Company’s extensive expertise in gas measurement in a smaller package, which can be mounted on stacks to lower the cost of emissions monitoring normally done from extractive systems.
Cemtrex, Inc. (CTEI), closed Monday's trading session at $0.59, up 2.80%, on 228,928 volume with 172 trades. The average volume for the last 60 days is 18,643 and the stock's 52-week low/high is $0.3512/$1.05.
VGTel, Inc. (VGTL)
PennyStockScholar, Research Driven Investor, OTCtipReporter, Stockdigest Report, David Cohen, PennyTrader, PickPennyStocks, Michael Stone, Growing Stocks Reports, Canadian Microcap Report, StockHideout, Stock Preacher, Stock Roach, Penny Stocks Finder, TheLightningPicks, and Beacon Equity Research reported earlier on VGTel, Inc. (VGTL), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Markets’ OTCQB, VGTel, Inc. operates as 360 Entertainment and Productions. The Company is a multi-platform enterprise offering products and support in the entertainment industry. It is concentrating on a strategy of growing and building business units via investments and acquisitions. Incorporated in 2002, VGTel has its corporate headquarters in Montebello, New York.
VGTel mainly develops, finances, produces, and distributes 4K UHD movie and film content (secured on top of five powerful platforms of key subsidiaries, affiliates and strategic partnerships,). In addition, it provides UHD scanning and post-production services and support.
The Company is looking to grow and expand its presence in a wide array of entertainment and event oriented acquisitions and investments, which are complementary to its present business platform.
Pertaining to Digital 4K Film Solutions, movies will be scanned from 15/70mm film to an 8K digital format. They will subsequently be downscaled to 4K and distributed for UHD broadcast and theatrical distribution. 4K UHD is four times the resolution of "HD."
The Company indicates that 4K UHD will be the new standard for television/home viewing. Most of these titles were originally shot in 15/70MM and other ultra high resolution formats suitable for IMAX/Giant Screen theaters. They have been digitally scanned at 4K or higher resolution.
In February, VGTel - 360 Entertainment & Productions announced that its wholly-owned subsidiary 4K film scanning studio, Motion Picture Scanning Services, Inc. (MPSS), upgraded its 4K scanning work flow. It is now providing 4K scanning services for films and programs, which were originally shot on 16mm and 35mm film stock. This expansion of services is VGTel’s response to the fast pace of growth occurring in the UHD/4K market.
Via MPSS it is aggressively expanding and growing its 4K business interests in light of commitments made by entertainment industry executives during CES 2015 and the emergence of 4K as the next standard for television.
VGTel, Inc. (VGTL), closed Monday's trading session at $0.0314, up 15.23%, on 1,154,662 volume with 54 trades. The average volume for the last 60 days is 1,345,577 and the stock's 52-week low/high is $0.011/$0.105.
Car Monkeys Group (CKMY)
The QualityStocks Daily Newsletter would like to spotlight Car Monkeys Group (CKMY). Today, Car Monkeys Group closed trading at $0.48, off by 0.04%, on 11,250 volume with 6 trades. The stock’s average daily volume over the past 60 days is 792, and its 52-week low/high is $0.10/$5.00.
Car Monkeys Group (CKMY), via CarMonkeys.com, is one of the largest and fastest growing online cars, vans and SUV parts distributors in the United States. Founded in 2010, the Wyckoff, New Jersey-based company formerly was known as Delaine Corporation and changed its name to Car Monkeys Group in February 2015.
With access to hundreds of thousands of parts, Car Monkeys sells used, high-quality, low-mileage automotive parts to consumers, retailers, truck and car fleet owners and auto repair facilities looking for a wide range of vehicle makes and models. Customers have access to a Part Finder section that helps them easily navigate and quickly locate the right parts they need.
Striving to provide customers a quick, hassle-free and convenient shopping experience, all parts ordered through CarMonkeys.com ship from one of the company’s numerous distributors and auto dismantling centers straight to the customer or their mechanic. Advantages such as a five-year unlimited mileage warranty, zero shipping costs, and a generous return policy further contribute to the increasing popularity of the Car Monkeys brand.
Automotive recycling plays a substantial role in the preservation of natural resources and reduction of demand for landfill space. According to the Automotive Recyclers Association, approximately 95% of vehicles retired from use are processed for recycling, saving an estimated 85 million barrels of oil that would have been used to manufacture new or replacement parts. As a rapidly growing and trusted automotive recycling company, Car Monkeys is positioned as a leading player in the broader $22 billion North American automotive recycling industry. Disclaimer
Car Monkeys Group Company Blog
Car Monkeys Group News:
Car Monkeys Group (CKMY) is “One to Watch”
Car Monkeys Group (CKMY) Continues Growth as one of the Country’s Largest Online Automobile Parts Distributors
Boreal Water Collection, Inc. (BRWC)
The QualityStocks Daily Newsletter would like to spotlight Boreal Water Collection, Inc. (BRWC). Today, Boreal Water Collection, Inc. closed trading at $0.0018, up 20.00%, on 3,308,732 volume with 22 trades. The stock’s average daily volume over the past 60 days is 1,161,970, and its 52-week low/high is $0.0012/$0.03.
Boreal Water Collection, Inc. (BRWC) is an established water bottler of premium private-labeled bottled water products tailored for each client’s particular need, be it publicity, promotion, marketing, internal use or a specific event. This emphasis on customization and quality has earned Boreal an impressive reputation, evidenced by its prestigious customer base of high-end beverage brands, retailer channels, high-end hotels and restaurant chains such as H&M, Mercedes, W Hotels, Dean & Deluca, Fred Water, Wat-aah, Saks Fifth Ave, Balance Water, NY Quin Hotel, Bouchon Bakery and Princeton University, just to name a few!
Located 90 miles north New York City, Boreal’s plant is only 17 miles from its well-protected source of natural spring water, a pristine and abundant spring source deep inside the heart of the Catskill Mountains. The spring’s exceptional geological and geographical features have created the perfect environment for Boreal’s low-mineral, sodium-free and well-balanced PH water. With exclusive exploitation rights, Boreal has a confirmed volume in excess of thousands of millions of gallons.
Boreal offers a line of award-winning water products, including functional enhanced water, infused water, carbonated water, vitamins enhanced water, flavored still or sparkling, minerals enhanced water, oxygenated water, electrolyte water, distilled water, alkaline water, caffeinated water and natural spring water.
Accommodating this plentiful water supply and range of product offerings, Boreal has established a 75,000-square foot manufacturing facility. Boreal can process a full range of water and bottle types and has the most creative staff for all private labeling needs. The company offers fully integrated turnkey service, made-to-order labeling along with distinctive water bottles. In short, Boreal is a “Boutique Bottler” and is focusing on becoming the leader of this attractive niche of the growing multi-billion dollar bottled water industry. Disclaimer
Boreal Water Collection, Inc. Company Blog
Boreal Water Collection, Inc. News:
Boreal Water Collection Releases Open Letter to Shareholders
Boreal Water Collection to Exhibit at China's Largest Food Show
Boreal Water Collection Reports Continued Growth in the Third Quarter of 2014, Sales Increase by 14% While Profitability Rises by 57%
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.064, up 12.87%, on 1,962,383 volume with 130 trades. The stock’s average daily volume over the past 60 days is 585,450, and its 52-week low/high is $0.0555/$0.241.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial
International Stem Cell Corporation to Conduct Parkinson's Disease Clinical Study in Australia
International Stem Cell Corporation to Present at Biotech Showcase(TM) 2015
Well Power Inc. (WPWR)
The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.0211, up 11.05%, on 713,410 volume with 41 trades. The stock’s average daily volume over the past 60 days is 90,410, and its 52-week low/high is $0.019/$0.83.
Well Power Inc. (WPWR) has secured the licensing rights to Texas with the first right of refusal on the other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and diluents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.
The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.
Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.
Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer
Well Power Inc. Company Blog
Well Power Inc. News:
Well Power - Letter from President to Shareholders
Well Power Inc. to host second webinar on proprietory micro-refinery technology
Well Power Inc. Information to be Available through S&P Capital IQ Corporation Records Program
IFAN Financial, Inc. (IFAN)
The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.31, up 1.64%, on 130,292 volume with 64 trades. The stock’s average daily volume over the past 60 days is 576,598, and its 52-week low/high is $0.0114/$1.01.
IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.
Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.
Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.
IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer
IFAN Financial, Inc. Company Blog
IFAN Financial, Inc. News:
IFAN Financial Reaches Technology Development Milestones
IFAN Financial, Inc. Announces Stock-Based Compensation Plan
IFAN Financial, Inc. Announces the Launch of New Website and Investor Relations Kit
Cleartronic, Inc. (CLRI)
The QualityStocks Daily Newsletter would like to spotlight Cleartronic, Inc. (CLRI). Today, Cleartronic, Inc. closed trading at $0.09, even for the day. The stock’s average daily volume over the past 60 days is 792, and its 52-week low/high is $0.04/$0.5499.
Cleartronic, Inc. (CLRI) is a technology holding company that creates and acquires operating subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises.
VoiceInterop, Inc., a wholly owned subsidiary, is a provider of patented IP communication gateways and communication software. Its gateways are marketed worldwide direct to customers as well as through a network of value added resellers. VoiceInterop has also developed an interoperable communication solution for use by airports. The company markets, installs and supports this interoperability solution directly to airports. International airports currently using the VoiceInterop communication solution include Dulles, Reagan, Omaha, Cincinnati, Green Bay and West Palm Beach.
A recent license agreement provides Cleartronic with the right to market Collabria LLC’s revolutionary ReadyOp™ command, control and communication platform. ReadyOp is a web-based application that integrates multiple databases and a robust communications platform supporting day-to-day activities for planning and managing small- and large-scale events. ReadyOp is designed for fast, efficient access to information and for communication with multiple persons, groups and agencies. ReadyOp is currently being used by numerous federal, state and local government agencies and private enterprises.
Backed by a management team committed to growing its business and finding ways to create value for shareholders, Cleartronic is well-positioned to grow in a broad array of markets. The company has a solid business plan in place that maximizes available resources for accelerated growth and has proven its ability to identify strong business opportunities. Disclaimer
Cleartronic, Inc. Company Blog
Cleartronic, Inc. News:
Cleartronic Announces Expanded License Agreement With Collabria LLC
Cleartronic Appoints Two New Members to Board of Directors
Cleartronic, Inc. (CLRI) Announces Capitalization Benefit Plan and Expansion of Board of Directors
Start Scientific, Inc. (STSC)
The QualityStocks Daily Newsletter would like to spotlight Start Scientific, Inc. (STSC). Today, Start Scientific, Inc. closed trading at $0.14, even for the day. The stock’s average daily volume over the past 60 days is 27,843, and its 52-week low/high is $0.10/$0.62.
Operating from headquarters in San Antonio, Texas, Start Scientific, Inc. (STSC) is in continual and aggressive pursuit of its corporate objective to take advantage of oil and gas exploration and development opportunities that are overlooked by mid-sized oil and gas companies.
Start Scientific’s is focused on developing leases and/or joint venture partnerships for its four primary projects in Mississippi, Texas, North Dakota and West Virginia. The projects include shallow, deep, and horizontal drilling opportunities. Geographically, the projects offer the company diversity for exploration and drilling.
As a progressive oil exploration, drilling, extraction and delivery company, Start Scientific relies on the vast knowledge of its management team, which provides more than half a century of combined industry experience. Leveraging strong industry contacts established by company founder Norris R. Harris, Start Scientific also explores partnership and joint-venture opportunities to further accelerate its growth.
Supported by a management team highly experienced in the workings of natural resources and business development, Start Scientific is well-positioned to achieve its mission to explore low-risk land lease opportunities on properties with known oil deposits, develop facilities on these properties to cost effectively extract the oil, and to distribute the refined oil for sale in the open market. Disclaimer
Start Scientific, Inc. Company Blog
Start Scientific, Inc. News:
Start Scientific, Inc. Signs Farmout Agreement With Durban Energy
Start Scientific, Inc. Acquires Option to Purchase 1,500 Acres of Leases in Matagorda County, Texas
Start Scientific, Inc. Signs Farmout Agreement for Flora Field, Madison County, Mississippi
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Boreal Water Collection, Inc. (BRWC) Releases Open Letter to Shareholders
- Car Monkeys Group (CKMY) is “One to Watch”
- Cleartronic, Inc. (CLRI) Announces Expanded License Agreement With Collabria LLC
- Coastal Integrated Services, Inc. (COLV) Announces Subsidiary's Nomination for Prestigious Award
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview
- eCareer Holdings, Inc. (ECHI) Reports 1000% Increase in Openreq.com Site Traffic, Seeks to Expand Salesforce
- Falcon Crest Energy (FCEN) Acquires Remaining Working Interest in Rocky Ford Field
- IFAN Financial, Inc. (IFAN) Reaches Technology Development Milestones
- International Stem Cell Corp. (ISCO) Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- Mobile Lads Corp. (MOBO) Purchases Majority of North American Shopping Network From Domark International
- One World Holdings, Inc. (OWOO) The One World Doll Project CEO Announces 2015 Revenue Projections in Stockholder Letter
- Pure Hospitality Solutions, Inc. (PNOW) anticipates $40 Million Oveedia Valuation with Divest and Focus Strategy
- Resort Savers, Inc. (RSSV) Closes $2M Investment
- Save The World Air, Inc. (ZERO) Deploys AOT(TM) Viscosity Reduction System on Condensate Pipeline in Eagle Ford
- Sibling Group Holdings, Inc. (SIBE) Announces Strategic Partnership for Global Growth; $3.75 Million Investment to Grow Business in China and Other Markets
- Sparta Commercial Services, Inc. (SRCO) Reports Continued Sales Growth
- Start Scientific, Inc. (STSC) Signs Farmout Agreement With Durban Energy
- VistaGen Therapeutics, Inc. (VSTA) and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) to host second webinar on proprietory micro-refinery technology
- Zenosense, Inc. (ZENO) Hospital Collaboration - 400 Person Lung Cancer Detection Trial